Equities

Adimmune Corp

4142:TAI

Adimmune Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)22.35
  • Today's Change0.150 / 0.68%
  • Shares traded1.14m
  • 1 Year change-32.48%
  • Beta--
Data delayed at least 20 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ADIMMUNE CORPORATION is a Taiwan-based company principally engaged in the research and development, processing, manufacture and trading of influenza vaccine products and non-flu vaccine products. The Company's products include Japanese encephalitis vaccines, tetanus vaccines, influenza vaccines, H1N1 influenza vaccines and tuberculin. The vaccine products are applied in the prevention of various infectious viruses. The tuberculin is applied in tuberculin purified protein derivative (PPD) test. The Company distributes its products within domestic market and to overseas markets, including other markets in Asia, Europe and Africa.

  • Revenue in TWD (TTM)1.66bn
  • Net income in TWD-607.92m
  • Incorporated1965
  • Employees564.00
  • Location
    Adimmune CorpNo.3Section 1, Tanxing Road, Tanzi DistrictTAICHUNG 427TaiwanTWN
  • Phone+886 425381220
  • Fax+886 425382105
  • Websitehttps://www.adimmune.com.tw/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cenra Inc8.94bn371.76m5.69bn1.40k25.510.7597.860.63631.501.5034.2850.260.71062.155.73--2.973.694.294.9637.1036.564.185.500.7054--0.297652.771.402.50-32.51-2.723.57-8.97
Formosa Pharmaceuticals Inc137.46m-200.59m5.93bn----3.70--43.11-1.49-1.491.0210.62-----------40.34---44.2184.63---145.95-2,488.28----0.0167--2,270.49--20.75---42.98--
Panion & BF Biotech Inc2.04bn121.33m7.63bn321.0062.934.0626.213.751.411.4123.7321.940.65461.729.66--3.904.085.725.6352.4352.375.965.930.880416.870.2717111.06-21.545.96-57.65-13.4735.39-3.23
Formosa Laboratories Inc4.59bn392.86m9.51bn480.0024.341.2312.502.073.253.2538.0664.430.33721.454.82--1.882.682.583.6143.8835.405.568.751.410.57890.307427.3815.8010.16-69.16-6.52-11.6032.22
Adimmune Corp1.66bn-607.92m9.54bn564.00--1.86--5.76-1.44-1.443.9311.920.18481.254.04---8.270.6867-10.190.773927.8230.11-44.753.041.99-24.750.328432.80-20.7216.77-319.91--38.05--
Standard Chem & Pharm Co Ltd6.71bn847.58m11.37bn1.13k13.421.927.101.694.744.7437.5033.050.60662.396.00--10.989.6820.0217.6143.8143.7518.1017.021.93--0.079560.346.6411.802.3917.4029.9712.47
SCI Pharmtech Inc1.41bn484.24m11.69bn241.0024.502.1616.678.273.993.9913.9845.360.22111.824.61--7.586.908.568.2627.1138.1834.2619.851.689.220.169242.3833.83-9.10-4.55-8.0044.67-16.35
Data as of Nov 21 2024. Currency figures normalised to Adimmune Corp's reporting currency: Taiwan Dollar TWD

Institutional shareholders

5.02%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 06 Nov 202413.07m3.04%
BlackRock Fund Advisorsas of 07 Nov 20243.62m0.84%
Dimensional Fund Advisors LPas of 07 Nov 20242.18m0.51%
BlackRock Advisors (UK) Ltd.as of 08 Nov 2024946.00k0.22%
SSgA Funds Management, Inc.as of 07 Nov 2024665.51k0.16%
Vanguard Fiduciary Trust Co.as of 31 Aug 2024386.77k0.09%
TIAA-CREF Investment Management LLCas of 31 Aug 2024266.00k0.06%
Vanguard Global Advisers LLCas of 30 Sep 2024250.00k0.06%
Dimensional Fund Advisors Ltd.as of 31 Aug 202481.62k0.02%
State Street Global Advisors Ltd.as of 07 Nov 202473.00k0.02%
More ▼
Data from 30 Sep 2024 - 14 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.